title: M-2000, as a new anti-inflammatory molecule in treatment of experimental nephrosis.
abstract: The therapeutic effect of M-2000 (C6H10O7) molecule was tested in Adriamycin-induced nephropathy. To induce experimental nephrosis, Adriamycin was given once by a single intravenous injection (7.5 mg/kg) through the tail vein. Six days after injection of Adriamycin, therapeutic protocol was developed by intraperitoneally (i.p) administration of 30 mg/kg M-2000 solution. Total of i.p. injections were 14, in which five injections were made every day and nine injections were carried out at regular 48-h intervals. Therapeutic protocol was terminated on day 28 and animals were killed on day 43. The treated patient rats showed a significant reduction in proteinuria, BUN, serum creatinine and serum cholesterol, as well as, administration of M-2000 could significantly diminish the serum level of interleukin-6 (IL-6) in treated animals compared to non-treated controls. Moreover, treatment with M-2000 significantly reduced number of glomerular leukocytes, Hypercellularity and hydropic change in capillary network within the renal cortex and decreased tubular casts. These data suggest that M-2000 therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrosis.
authors.affiliation: Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. a_mirshafiey@yahoo.com
authors.forename: Abbas
authors.initials: A
authors.lastname: Mirshafiey
authors.forename: Bernd H A
authors.initials: BH
authors.lastname: Rehm
authors.forename: Ahmad Ali
authors.initials: AA
authors.lastname: Sahmani
authors.forename: Aboulghasem
authors.initials: A
authors.lastname: Naji
authors.forename: Alireza
authors.initials: A
authors.lastname: Razavi
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D005260:Female; D006838:Hydrocarbons / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D015850:Interleukin-6 / Q000097:blood / Q000276:immunology; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D007677:Kidney Function Tests; D008055:Lipids / Q000097:blood; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011507:Proteinuria / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006838:Hydrocarbons; D015850:Interleukin-6; D008055:Lipids; C513976:M-2000 compound; D003404:Creatinine